Directorate Change

Provexis PLC
09 December 2005


9 December 2005

                                  PROVEXIS PLC
                         ('Provexis' or the 'Company')

   Appointment of Finance Director Designate and Company Secretary Designate

Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, announces the appointment of Stewart William
Slade, 56, as Finance Director designate and Company Secretary designate, with
immediate effect. Stewart succeeds Doug Gardner, who will step down from his
role as interim Director of Finance, a non-Board position, on 14 December.
Stewart will formally assume his position as Finance Director and Company
Secretary and join the Board of Provexis following the Company's Board Meeting
on 10th January 2006.

Stewart joins Provexis from Senetek PLC ('Senetek'), a life sciences company,
headquartered in the U.S, engaged in the development and marketing of
proprietary pharmaceutical and cosmeceutical products that fulfil unmet consumer
needs related to aging. At Senetek, Stewart was Chief Financial Officer and
Company Secretary from 1998 until 2003 when he was appointed Vice President of
European Operations, whilst continuing to act as Company Secretary.

Stewart, who began his career as a research and development biochemist with the
Smith Kline Corporation in 1971, qualified as a chartered accountant at Coopers
& Lybrand, London in 1978. He joined Colgate Palmolive UK in 1980 as an
international accountant and proceeded to work with Colgate Palmolive's Indian
and then Caribbean operations as financial controller. In 1986 he joined DuBois
Chemicals Ltd, the speciality chemicals and industrial cleaning systems
subsidiary of Chemed Corporation, as Financial Director and Company Secretary.
Following the acquisition of DuBois by Diversey Limited (now Johnson Diversey)
in 1991, Stewart was appointed Financial Director of the European Operations
group at Diversey.

Commenting on the appointment, Dr Stephen Franklin, Chief Executive of Provexis,
said: 'We are delighted to welcome Stewart to the company. He has excellent
credentials and a wealth of experience having worked with major chemical and
healthcare companies. We look forward to benefiting from the valuable
contribution that his international, operational and financial expertise can
bring to the company.'

There are no further disclosures to be made in accordance with Rule 17 and
schedule 2 (g) of the AIM Rules.

For further information please contact:

Provexis plc
Dr Stephen Franklin 0208 392 6631

Bell Pottinger Corporate & Financial
Ann-Marie Wilkinson/Emma Kent 020 7861 3232




                      This information is provided by RNS
            The company news service from the London Stock Exchange